Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis

Fingolimod is a selective immunosuppressive agent approved worldwide for the treatment of relapsing-remitting multiple sclerosis (MS), a chronic and potentially disabling neurological condition. Randomized double-blind clinical trials have shown that fingolimod significantly reduces relapse rate and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gajofatto, Alberto, Turatti, Marco, Monaco, Salvatore, Benedetti, Maria Donata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686225/
https://www.ncbi.nlm.nih.gov/pubmed/26715860
http://dx.doi.org/10.2147/DHPS.S69640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686225/
https://www.ncbi.nlm.nih.gov/pubmed/26715860
http://dx.doi.org/10.2147/DHPS.S69640

Ejemplares similares